These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37340403)

  • 1. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients.
    Abu Al Karsaneh O; Al Anber A; ALQudah M; Al-Mustafa S; AlMa'aitah H; Sughayer M
    Diagn Pathol; 2023 Jun; 18(1):75. PubMed ID: 37340403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.
    Lee Y; Lee B; Choi YL; Kang DW; Han J
    Mod Pathol; 2024 Jun; 37(6):100490. PubMed ID: 38588887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Genomic Features of
    Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
    JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
    Lim TH; Lim AST; Tien SL; Tan PH
    Ann Diagn Pathol; 2022 Jun; 58():151935. PubMed ID: 35313158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
    Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
    Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
    Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer.
    Xia Q; Zhu Z; Wang J; Situ D; Zhou N; Jang W
    Tumour Biol; 2012 Oct; 33(5):1719-25. PubMed ID: 22736332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human epidermal growth factor receptor 2 neu expression in head and neck squamous cell cancers and its clinicopathological correlation: Results from an Indian cancer center.
    Vats S; Ganesh MS; Agarwal A
    Indian J Pathol Microbiol; 2018; 61(3):313-318. PubMed ID: 30004046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p95HER2 truncated form in resected non-small cell lung cancer.
    Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
    J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
    Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
    Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
    Ninomiya K; Hata T; Yoshioka H; Ohashi K; Bessho A; Hosokawa S; Ishikawa N; Yamasaki M; Shibayama T; Aoe K; Kozuki T; Harita S; Ueda Y; Murakami T; Fujimoto N; Yanai H; Toyooka S; Takata M; Hotta K; Kiura K;
    Chest; 2019 Aug; 156(2):357-366. PubMed ID: 31072612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
    Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
    Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
    Liu L; Shao X; Gao W; Bai J; Wang R; Huang P; Yin Y; Liu P; Shu Y
    J Thorac Oncol; 2010 Dec; 5(12):1922-32. PubMed ID: 21155183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.
    Zhuo X; Guo H; Ma J; Lai J; Liu L; Yin K; Zhao J; Wang J; Jiang F; Xu W; Yuan X; Lin X; Fu G
    J Cancer Res Clin Oncol; 2023 May; 149(5):2029-2039. PubMed ID: 35829744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.